Update on immunization

Current Opinion in Pediatrics

Volumn 8, Issue 1, 1996, Pages 21-27

  Forrest, Jill M ^a   Burgess, Margaret A ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE;

CHICKENPOX; DIPHTHERIA; DRUG EFFICACY; EPIDEMIC; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH PROGRAM; HEPATITIS A; HUMAN; IMMUNIZATION; MEASLES; MENINGOCOCCOSIS; MUMPS; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RUBELLA; UNITED STATES;

CHICKENPOX; CHILD; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; MEASLES VACCINE;

EID: 0029918232     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199602000-00006     Document Type: Review

References (102)

1. Committee on Infectious Diseases: Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995, 95:791-796. A comprehensive review of varicella zoster epidemiology, development of varicella zoster vaccine, and detailed instructions for its use.
2. Hughes P, LaRussa P, Pearce JM, Lepow M, Steinberg S, Gershon A: Transmission of varicella-zoster virus from a vaccinee with leukemia, demonstrated by polymerase chain reaction. J Pediatr 1994, 124:932-935.
3. Friedman Ross L, Lantos JD: Immunisation against chickenpox. BMJ 1995, 310:2-3.
4. Ferson MJ: Another vaccine, another treadmill? J Paediatr Child Health 1995, 31:3-5.
5. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L: Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994, 140:81-104.
6. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M: Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994, 343:1547-1550. The definitive study of varicella zoster infection in pregnancy, from the United Kingdom and Germany, with enough cases to provide reliable estimates for risk counseling.
7. Gershon AA: Present and future challenges of immunizations on the health of our patients. Pediatr Infect Dis J 1995, 14:445-449. A state-of-the-art discussion about well-controlled and problem areas of vaccination in the USA.
8. Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR: Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994, 170:522-526.
9. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S: Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994, 94:524-526.
10. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, Cnaan A, Starr SE: Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995, 20:316-319.
11. Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, Clements D, Kumar ML, Reisinger K, Blatter M, Starr SS, Staehle B, Ngai A, White CJ: Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 1995, 172:217-219.
12. Nader S, Bergen R, Sharp M, Arvin MA: Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 1995, 171:13-17.
13. Isaacs D, Menser M: Modern vaccines: measles, mumps, rubella, and varicella. Lancet 1990, 335:1384-1387.
14. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K: The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994, 331:1397-1402. A classic example of how a country can successfully eliminate infectious diseases using currently available vaccines.
15. Heisler MB, Richmond JB: Lessons from Finland's successful immunization program. N Engl J Med 1994, 331:1446-1447.
16. Children's Vaccine Initiative Ad Hoc Committee: Measles control: resetting the agenda. A report of the Children's Vaccine Initiative Ad Hoc Committee on an investment strategy for measles control. J Infect Dis 1994, 170(suppl 1):S1-S66. Report of a conference held in Bellagio, Italy, in March 1993, covering all aspects of measles and its control.
17. Mulholland K: Measles and pertussis in developing countries with good vaccine coverage. Lancet 1995, 345:305-307.
18. McLean AR: After the honeymoon in measles control. Lancet 1995, 345:272.
19. Khuri-Bulos NA: Measles in Jordan: a prototype of the problems with measles in developing countries. Pediatr Infect Dis J 1995, 14:22-26.
20. Carson MM, Spady DW, Albrecht P, Beeler JA, Thipphawong J, Barreto L, Grimsrud KM, Pabst HF: Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J 1995, 14:17-22.
21. Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML: Measles vaccine immunogenicity in 6- versus 15-month-old infants bom to mothers in the measles vaccine era. Pediatrics 1994, 93:939-944.
22. Samb B, Aaby P, Whittle HC, Seck AMC, Rahman S, Bennett J, Markowitz L, Simondon F: Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995, 14:203-209.
23. Kim SK, Son BK, Chung CY, Ahn YM, Park CY, Lee HJ: Efficacy of measles vaccine during the 1993 measles epidemic in Korea. Pediatr Infect Dis J 1995, 14:346-349.
24. Wiratunga EBP, O'Brien J: National measles and rubella vaccination campaign. BMJ 1995, 310:1532.
25. Miller E: The new measles campaign. BMJ 1994, 309:1102-1103. Discussion of a planned mass immunization campaign to prevent an epidemic predicted by modeling.
26. Semba RD, Munasir Z, Beeler J, Akib A, Muhilal, Audet S, Sommer A: Reduced seroconversion to measles in infants given vitamin A with measles vaccination. Lancet 1995, 345:1330-1332. A worrying finding for developing countries, where vitamin A administration has an important impact on mortality in infants and young children.
27. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ: Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995, 345:1071-1074.
28. Patriaca PA, Beeler JA: Measles vaccination and inflammatory bowel disease [editorial]. Lancet 1995, 345:1062-1063.
29. Farrington P, Miller E: Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995, 345:1362.
30. Minor PD: Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995, 345:1362-1363.
31. MacDonald TT: Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995, 345:1363.
32. Aickin R, Hill D, Kemp A: Measles immunisation in children with allergy to egg. BMJ 1994, 309:223-225.
33. Freigang B, Jadavji TP, Freigang DW: Lack of adverse reactions to measles, mumps, and rubella vaccine in egg-allergic children. Ann Allergy 1994, 73:486-488.
34. James JM, Burks AW, Roberson PK, Sampson HA: Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995, 332:1262-1266.
35. Plesner A-M: Gait disturbance after measles, mumps, and rubella vaccine. Lancet 1995, 345:316.
36. Nussinovitch M, Harel L, Varsano I: Arthritis after mumps and measles vaccination. Arch Dis Child 1995, 72:348-349.
37. Popovic T, Wharton M, Wenger JD, McIntyre L, Wachsmuth IK: Are we ready for diphtheria? A report from the Diphtheria Diagnostic Workshop, Atlanta, 11 and 12 July 1994. J Infect Dis 1995, 171:765-767. An overview of diphtheria around the world since 1990.
38. Centers for Disease Control: Diphtheria epidemic: new independent states of the former Soviet Union, 1990-1994 and diphtheria acquired by U.S. citizens in the Russian Federation and Ukraine-1994. JAMA 1995, 273:1250-1252.
39. Maple PA, Efstratiou A, George RC, Andrews NJ, Sesardic D: Diphtheria immunity in UK blood donors. Lancet 1995, 345:963-965.
40. Rabinovich R, Robblns A: Pertussis vaccines: a progress report JAMA 1994, 271:68-69.
41. Marwick C: Acellular pertussis vaccine hailed for infants. JAMA 1995, 274:446-447. Preliminary reports of new vaccines with fewer side effects.
42. Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME, Elmwood Pediatric Associates, Pennridge Pediatric Associates: Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Arch Pediatr Adolesc Med 1994, 148:503-507.
43. Podda A, De Luca EC, Contu B, Furlan R, Maida A, Moiraghi A, Stramare D, Titone L, Uxa F, Di Pisa F, Peppoloni S, Nencioni L, Rappuoli R, Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine: Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. J Pediatr 1994, 124:921-926.
44. Christie CDC, Mare ML, Marchant CD, Reising SF: The 1993 epidemic of pertussis in Cincinnati: resurgence of disease in a highly immunized population of children. N Engl J Med 1994, 331:16-21.
45. Gale JL, Thapa PB, Wassilak SGF, Bobo JK, Mendelman PM, Foy HM: Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine: a population-based case-control Study. JAMA 1994, 271:37-41.
46. Centers for Disease Control: Progress toward global eradication of poliomyelitis, 1988-1993. JAMA 1994, 272:345-346.
47. Centers for Disease Control: Progress toward global poliomyelitis eradication, 1985-1994. JAMA 1995, 273:1408-1409.
48. Strebel PM, Ion-Nedelcu NI, Baughman AL, Sutter RW, Cochi SL: Intramuscular injections within 30 days of immunization with oral poliovirus vaccine: a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med 1995, 332:500-506. Highlights the importance of "provocation" paralysis in vaccinees.
49. Dalakas MC, Illa I, Leon-Monzon M: Intramuscular injections and vaccine-associated poliomyelitis. N Engl J Med 1995, 333:62.
50. Strebel PM, Sutter RW, Pallansch MA, Cochi SL: Intramuscular injections and vaccine-associated poliomyelitis. N Engl J Med 1995, 333:64.
51. Kobayashi Y, Chiba Y, Hikita K, Kusumoto K: Collaboration between Japan and China towards poliomyelitis eradication. Lancet 1995, 345:455.
52. Yang B, Zhang J, Otten MW, Kusumoto K, Jiang T, Zhang R, Zhang L, Wang K-A: Eradication of poliomyelitis: progress in the People's Republic of China. Pediatr Infect Dis J 1995, 14:308-314.
53. Cochi SL, Orenstein WA: Commentary: China's giant step toward the global eradication of poliomyelitis. Pediatr Infect Dis J 1995, 14:315-316.
54. Takala AK, Peltola H, Eskola J: Disappearance of epiglottitis during large-scale vaccination with Haemophilus influenzae type b conjugate vaccine among children in Finland. Laryngoscope 1994, 104:731-735. Describes the virtual elimination of this condition by vaccination over 6 years.
55. van Alphen L, Spanjaard L, van der Ende A, Dankert J: Predicted disappearance of Haemophilus inftuenzae type b meningitis in Netherlands. Lancet 1994, 344:195.
56. Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MPE, Macfarlane JA, Haworth EA, Kiddle M, Shribman S, Roberts JStC, Moxon ER: Efficacy of Haemophilus influenzae type b conjugate vaccine PRPT. Lancet 1994, 344:362-366.
57. Marsh MJ, Murdoch IA: Acute epiglottitis after Hlb vaccination. Lancet 1994, 344:829.
58. Englund JA, Glezen WP, Turner C, Harvey J, Thompson C, Siber GR: Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J Infect Dis 1995, 171:99-105.
59. 197 protein vaccines in infancy. Arch Pediatr Adolesc Med 1994, 148:620-625.
60. De Febres OC, Decker MD, Estopinan M, Bordones G, Edwards KM: Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 1994, 13:635-639.
61. Greenberg DP, Lieberman JM, Marcy SM, Wong VK, Partridge S, Chang S-J, Chiu C-Y, Ward JI: Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995, 126:206-211.
62. Anderson EL, Decker MD, Englund JA, Edwards KM, Anderson P, McInnes P, Belshe RB: Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA 1995, 273:849-853.
63. Herbert MA, Heath PT, Mayon-White RT: Meningococcal vaccines for the United Kingdom. Commun Dis Rep CDR Rev 1995, 5:R130-R135.
64. Jackson LA, Schuchat A, Reeves MW, Wenger JD: Serogroup C meningococcal outbreaks in the United States: an emerging threat JAMA 1995, 273:383-389.
65. Whalen CM, Hockin JC, Ryan A, Ashton F: The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992: emergence of a virulent clone of Neisseria meningitidis. JAMA 1995, 273:390-394.
66. Riordan FAI, Marzouk O, Thomson APJ, Sills JA, Hart CA: Mortality from group C meningococcal disease: a case for a conjugate vaccine? Eur J Pediatr 1994, 153:821-824.
67. Twumasi PA, Kumah S, Leach A, O'Dempsey TJD, Ceesay SJ, Todd J, Broome CV, Carlone GM, Pais LB, Holder PK, Plikaytis BD, Greenwood BM: A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995, 171:632-638.
68. Tilzey AJ: Hepatitis B vaccine boosting: the debate continues. Lancet 1995, 345:1000-1001.
69. Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, Mendy M, Whittle HC: Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994, 169:1374-1376.
70. Whittle HC, Maine N, Pilkington J, Memdy M, Fortuin M, Bunn J, Allison L, Howard C, Hall A: Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995, 345:1089-1092.
71. Marion SA, Tomm Pastore M, Pi DW, Mathias RG: Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994, 140:734-746.
72. Mangione R, Stroffolini T, Tosti ME, Fragapani D, Mele A: Delayed third hepatitis B vaccine dose and immune response. Lancet 1995, 345:1111-1112.
73. West DJ, Watson B, Lichtman J, Hesley TM, Hedberg K: Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J 1994, 13:745-747.
74. Kollar LM, Rosenthal SL, Biro FM: Hepatitis B vaccine series compliance in adolescents. Pediatr Infect Dis J 1994, 13:1006-1008.
75. Schiff GM, Sherwood JR, Zeldis JB, Krause DS: Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995, 16:12-17.
76. Marchou B, Excler J-L, Bourderioux C, Salaun J, Picot N, Yvonnet B, Cerisier J-E, Salomon H, Auvergnat J-C: A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J Infect Dis 1995, 172:258-260.
77. Hollinger FB: An overview of the clinical development of hepatitis A vaccine. J Infect Dis 1995, 171(suppl 1):S1-S77. Report of a conference held in Florida in February 1994, covering the epidemiology and prevention of hepatitis A.
78. André FE: Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. J Infect Dis 1995, 171(suppl 1):S33-S39.
79. Margolis HS, Alter MJ: Will hepatitis A become a vaccine-preventable disease? Ann Intern Med 1995, 122:464-465.
80. Brewer MA, Edwards KM, Decker MD. Who should receive hepatitis A vaccine? Pediatr Infect Dis J 1995, 14:258-260.
81. Al-Attar I, Reisman J, Muehlmann M, McIntosh K: Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995, 14:149-151.
82. Rudy BJ, Rutstein RM, Pinto-Martin J: Responses to measles immunization in children infected with human immunodeficiency virus. J Pediatr 1994, 125:72-74.
83. Peters VB, Sood SK: Immunity to Haemophilus influenzae type b polysaccharide capsule in children with human immunodeficiency virus infection immunized with a single dose of Haemophilus vaccine. J Pediatr 1994, 125:74-77.
84. Kale KL, King JC, Farley JJ, Vink PE, Cimino CO, Paradiso PR: The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants. Pediatr Infect Dis J 1995, 14:350-354.
85. Arpadi SM, Back S, O'Brien J, Janoff EN: Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. J Pediatr 1994, 125:77-79.
86. Zuccotti GV, Riva E, Rumine P, Locatelli V, Fiocchi A, Tordato G, Giovannini M: Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Pediatr 1994, 125:70-72.
87. Choudhury SA, Peters VB: Responses to hepatitis B vaccine boosters in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995, 14:65-67.
88. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995, 345:1342-1344.
89. Beale J: An attenuated vaccine for AIDS? Lancet 1995, 345:1318-1319.
90. Mascola JR, McNeil JG, Burke DS: AIDS vaccines: are we ready for human efficacy trials? JAMA 1994, 272:488-489.
91. Belshe RB, Bolognesi DP, Clements ML, Corey L, Dolin R, Mestecky J, Mulligan M, Stablein D, Wright P: HIV infection in vaccinated volunteers. JAMA 1994, 272:431.
92. Simasathien S, Migasena S, Samakoses R, Pitisuttitham P, Sangaroon P, Aree C, Bishop R, Bugg H, Davidson BL, Vesikari T: Vaccination of Thai infants with rhesus-human reassortant tetravalent oral rotavirus vaccine. Pediatr Infect Dis J 1994, 13:590-596.
93. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, for the US Rotavirus Vaccine Efficacy Group: Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995, 273:1191-1196.
94. Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, Cabezas C, Watts DM, Svennerholm A-M, Sadoff JC, Taylor DN: Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994, 344:1273-1276.
95. Steffen R: New cholera vaccines-for whom? Lancet 1994, 344:1241-1242.
96. Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN: Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 1995, 345:949-952. Offers exciting prospects for a cholera-free future.
97. White NJ: Tough test for malaria vaccine.Lancet 1994, 344:1172-1173.
98. Alonso PL, Smith T, Armstrong Schellenberg JRM, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, et al.: Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994, 344:1175-1181.
99. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, et al.: Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995, 171:1576-1585.
100. Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefsons, Steinhoff MC, Wilson MH, Harris DO, Clements ML, Murphy BR: A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995, 171:1107-1114.
101. Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, Smith DH: Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 1994, 13:792-798.
102. Ellis RW, Douglas RG Jr: New vaccine technologies. JAMA 1994, 271:929-931.